Nick Williams has been trying to sell Jake Arrieta on the Phillies

Al Bello/Getty Images
18 Comments

CSN Philly’s Jim Salisbury reports that Phillies outfielder Nick Williams has been working out daily with free agent starter Jake Arrieta in Austin. The right-hander, who won the 2015 National League Cy Young Award, still remains teamless with spring training less than a month away. Williams has been trying to sell Arrieta on joining the Phillies.

Williams said of Arrieta, “He loves it here [Austin]. He has told me he likes working with young guys. I’m like, ‘All right, come on up.’ But I’m not writing the check. I don’t know what he wants. I don’t really dig into that because I’m not really in his position.”

On GM Matt Klentak’s hunt for pitching help, new manager Gabe Kapler said, “The pursuit is very real. I have a lot of trust that we’ll either go in [to spring training] with a new toy or we will pass on the opportunity because we’re better off giving this collection of pitchers a really healthy look because we thought that we could go acquire that piece a little bit later on this season or in the offseason next year.”

Arrieta, who turns 32 years old in March, went 14-10 with a 3.53 ERA and a 163/55 K/BB ratio in 168 1/3 innings last season with the Cubs. The Cubs, Cardinals, and Brewers have been linked to Arrieta this month.

Presently, the Phillies’ starting rotation figures to include Aaron Nola, Jerad Eickhoff, and Vince Velasquez along with some combination of Nick Pivetta, Ben Lively, Zach Eflin, Mark Leiter, and Jake Thompson. Arrieta would certainly amount to a big upgrade in the starting rotation and could make the Phillies a more attractive landing spot for Bryce Harper or Manny Machado, who become free agents after the 2018 campaign. The Phillies are expected to be in the mix for either or both players.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.